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Contents l ists avai lable at ScienceDirectLetter and ReplyPulmonary hypertension in chronic kidney disease: what
could change the fate?To the Editor: echocardiography (before or after HD, data not shown). How-Recently, the interest is increasing in studying the associa-
tion between pulmonary hypertension (PH) and chronic kidney
disease (CKD). PH is rare in general but may be present in
30e40% (on the basis of echocardiographic studies) of the pa-
tients with end-stage renal disease, being associated with
high morbidity and mortality [1]. The reason why PH is
frequently associated with CKD or end-stage renal disease is
still unclear and presumed to bemultifactorial [2]. In the results
from the Chronic Renal Insufﬁciency Cohort study group, the
likelihood of prevalent PH was increased with older age, pres-
ence of anemia, left ventricular hypertrophy, and lower levels
of left ventricular ejection fraction [1].
In the past issue of this Journal, Kim et al [3] investigated as-
sociations between PH, peripheral vascular calciﬁcations (VCs),
and major cardiovascular events in dialysis patients. In this
retrospective study, echocardiography and plain radiographs
were used to estimate pulmonary artery systolic pressure
and simple VC score of the hands and pelvis, respectively.
The authors concluded that severe VCs were independently
associated with PH and that PH was predictive of major cardio-
vascular events. Accordingly, they suggested that careful atten-
tion should be paid to the presence of VCs and PH in dialysis
patients because of the occurrence of major cardiovascular
events.
Then, how can we block the bad scenario beginning from
VCs? The authors stated that to prevent VC, early initiation of
hyperphosphatemia management or use of nonecalcium-
based phosphate binders is necessary in CKD patients.
I doubt if either early control of hyperphosphatemia or use of
nonecalcium-based phosphate binders has clear evidence to
support their application in clinical practice. Actually, VCs are
most often detected incidentally on imaging studies for other
purposes. Most nephrologists do not screen or attempt to
quantify VC in all CKD patients because no speciﬁc therapy is
available beyond careful attention to calcium and phosphate
balance.
Finally, the timing of echocardiography may be important
in dialysis patients. The authors were also aware of the possi-
bility of inconstancy in timing of echocardiography according
to hemodialysis (HD) session, but they found that the preva-
lence of PH was not statistically affected by the timing ofhttp://dx.doi.org/10.1016/j.krcp.2015.12.002
2211-9132/Copyright © 2016. The Korean Society of Nephrology. Published b
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ever, reproducibility of their data may need to be tested. Pre-
vious studies have reported that pulmonary arterial pressure
values tend to regress after each HD session [4,5]. Appropriate
dialytic therapy would be the most feasible tool to control PH
because volume status may affect diastolic function of the
heart.
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In reply:
We appreciate your interest in our recent article entitled
“Relationship between pulmonary hypertension, peripheral
vascular calciﬁcation, andmajor cardiovascular events in dialysis
patients” [1]. Chronic kidney diseasewith amilieu of accelerated
extraosseous calciﬁcation may result in vascular calciﬁcation
(VC) not only in peripheral artery but also in the coronary or
pulmonary arteries [2,3]. Theoretically, VC could involve
pulmonary vascular beds and subsequently increase the risk of
pulmonary hypertension. Our group previously demonstrated
that low intact PTH (parathyroid hormone) and diabetes were
independent risk factors for predicting VC and also that simple
VC score 1 was a signiﬁcant variable for predicting severe cor-
onary artery calciﬁcation in patients with peritoneal dialysis [2].
As you pointed out in the letter, VC is still most often
detected incidentally on imaging studies obtained for other
purposes. However, we need to pay attention to central VCs
including pulmonary vascular beds and coronary arteries that
can substantially affect cardiovascular outcomes. Relatively
easy and inexpensive procedures can detect them during our
routine clinical practices in chronic kidney disease patients. In
addition, although deﬁnitive treatments or preventive mea-
sures are not currently possible, we need to carefully monitor
these patients with VCs for the presence of ischemic heart dis-
ease or pulmonary hypertension. Speciﬁc treatment strategies
against VC may be realized in the near future.
With regard to timing of echocardiography in measuring
pulmonary artery pressure, we completely agree with your
our study might have affected the results, and we recognized it
as a limitation of our study. To verify this, future larger prospec-
tive studies will be required.
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